Adjuvant mitotane for adrenocortical cancer--a recurring controversy.
Huang
Hui
H
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. huangh@mail.nih.gov
Fojo
Tito
T
D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008939:Mitotane / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D012008:Recurrence
D018931:Antineoplastic Agents, Hormonal; D008939:Mitotane